Aptimmune Biologics is creating valuable, safe, and effective mucosal vaccines to combat economically challenging swine diseases. Aptimmune Biologics specializes in developing revolutionary mucosal vaccines that provide unsurpassed efficacy against the viral diseases most costly to the swine industry and the prevention of two major diseases – Porcine Reproductive and Respiratory Syndrome virus (PRRSV) and influenza.

For more information, visit Aptimmune Biologics or follow their updates on:



  • $8.9m
  • 9

Aptimmune Biologics Articles

With Help From The Yield Lab, Aptimmune Biologics Gains Access to the Worldwide Market

The Yield Lab St. Louis Announces 2017 Portfolio